Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
TORONTO, ONTARIO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended June 30, 2021. The Company also provided an update on its pre-clinical and clinical development programs.
- TORONTO, ONTARIO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (Aeterna or the Company), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended June 30, 2021.
- In consultation with The University of Sheffield, UK, selected AEZS-150 as the lead candidate in the Company's delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program.
- In February 2021, Aeterna entered into an exclusive option agreement with Julius-Maximilians-University to evaluate a preclinical, potential COVID-19 vaccine developed at Julius-Maximilians-University.
- The Company had $69.9 million cash and cash equivalents at June 30, 2021 (March 31, 2021 73.4 million).